Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of Pamiparib in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma

Next Previous
X
Search
Trial Profile

A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of Pamiparib in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pamiparib (Primary) ; Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BeiGene

    • Most Recent Events

    • 14 Apr 2021 Status changed from active, no longer recruiting to completed.
    • 03 Mar 2021 Planned End Date changed from 31 Dec 2020 to 30 Jun 2021.
    • 04 Sep 2020 Planned End Date changed from 31 Oct 2021 to 31 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top